325 related articles for article (PubMed ID: 35943535)
1. Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use.
Foletto VS; da Rosa TF; Serafin MB; Hörner R
Eur J Clin Pharmacol; 2022 Oct; 78(10):1601-1611. PubMed ID: 35943535
[TBL] [Abstract][Full Text] [Related]
2. The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis.
Nakhaee H; Zangiabadian M; Bayati R; Rahmanian M; Ghaffari Jolfayi A; Rakhshanderou S
PLoS One; 2022; 17(10):e0267423. PubMed ID: 36201406
[TBL] [Abstract][Full Text] [Related]
3. Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants.
Oskotsky T; Maric I; Tang A; Oskotsky B; Wong RJ; Aghaeepour N; Sirota M; Stevenson DK
JAMA Netw Open; 2021 Nov; 4(11):e2133090. PubMed ID: 34779847
[TBL] [Abstract][Full Text] [Related]
4. Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19.
Mahdi M; Hermán L; Réthelyi JM; Bálint BL
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409171
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 Outcomes: Does the Use of Psychotropic Drugs Make a Difference? Accumulating Evidence of a Beneficial Effect of Antidepressants-A Scoping Review.
Bonnet U; Juckel G
J Clin Psychopharmacol; 2022 May-Jun 01; 42(3):284-292. PubMed ID: 35420565
[TBL] [Abstract][Full Text] [Related]
6. Do the Selective Serotonin Reuptake Inhibitor Antidepressants Fluoxetine and Fluvoxamine Reduce Mortality Among Patients With COVID-19?
Hoertel N
JAMA Netw Open; 2021 Nov; 4(11):e2136510. PubMed ID: 34779851
[No Abstract] [Full Text] [Related]
7. Rapid response to selective serotonin reuptake inhibitors in post-COVID depression.
Mazza MG; Zanardi R; Palladini M; Rovere-Querini P; Benedetti F
Eur Neuropsychopharmacol; 2022 Jan; 54():1-6. PubMed ID: 34634679
[TBL] [Abstract][Full Text] [Related]
8. A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications.
Prasanth MI; Wannigama DL; Reiersen AM; Thitilertdecha P; Prasansuklab A; Tencomnao T; Brimson S; Brimson JM
Sci Rep; 2024 Jun; 14(1):13462. PubMed ID: 38862591
[TBL] [Abstract][Full Text] [Related]
9. Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives?
Pashaei Y
J Clin Neurosci; 2021 Jun; 88():163-172. PubMed ID: 33992179
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis.
Deng J; Rayner D; Ramaraju HB; Abbas U; Garcia C; Heybati K; Zhou F; Huang E; Park YJ; Moskalyk M
Clin Microbiol Infect; 2023 May; 29(5):578-586. PubMed ID: 36657488
[TBL] [Abstract][Full Text] [Related]
11. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.
Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
Cochrane Database Syst Rev; 2015 May; 2015(5):CD011681. PubMed ID: 25931277
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.
Sánchez C; Hyttel J
Cell Mol Neurobiol; 1999 Aug; 19(4):467-89. PubMed ID: 10379421
[TBL] [Abstract][Full Text] [Related]
13. [Selective serotonin reuptake inhibitor(SSRI)].
Motohashi N
Nihon Rinsho; 2001 Aug; 59(8):1519-22. PubMed ID: 11519151
[TBL] [Abstract][Full Text] [Related]
14. [Use of antidepressant drugs in schizophrenic patients with depression].
Micallef J; Fakra E; Blin O
Encephale; 2006; 32(2 Pt 1):263-9. PubMed ID: 16910628
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic Aspects of COVID-19 Management and Post-COVID-19 Depression Treatment with Fluvoxamine.
Dobrodeeva V; Abdyrahmanova A; Astafeva D; Smirnova D; Cumming P; De Sousa A; Davydkin I; Yashikhina A; Shnayder N; Nasyrova R
Psychiatr Danub; 2022 Sep; 34(Suppl 8):25-30. PubMed ID: 36170697
[TBL] [Abstract][Full Text] [Related]
16. Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.
Facente SN; Reiersen AM; Lenze EJ; Boulware DR; Klausner JD
Drugs; 2021 Dec; 81(18):2081-2089. PubMed ID: 34851510
[TBL] [Abstract][Full Text] [Related]
17. Antidepressants for people with epilepsy and depression.
Maguire MJ; Weston J; Singh J; Marson AG
Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010682. PubMed ID: 25464360
[TBL] [Abstract][Full Text] [Related]
18. The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue.
Zimniak M; Kirschner L; Hilpert H; Geiger N; Danov O; Oberwinkler H; Steinke M; Sewald K; Seibel J; Bodem J
Sci Rep; 2021 Mar; 11(1):5890. PubMed ID: 33723270
[TBL] [Abstract][Full Text] [Related]
19. Fluoxetine hydrochloride loaded lipid polymer hybrid nanoparticles showed possible efficiency against SARS-CoV-2 infection.
Khater SE; El-Khouly A; Abdel-Bar HM; Al-Mahallawi AM; Ghorab DM
Int J Pharm; 2021 Sep; 607():121023. PubMed ID: 34416332
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of action of fluvoxamine for COVID-19: a historical review.
Hashimoto Y; Suzuki T; Hashimoto K
Mol Psychiatry; 2022 Apr; 27(4):1898-1907. PubMed ID: 34997196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
